Company intelligence / Profile preview

PamBio

Ownership: Private
Development stage: Preclinical

Overview

PamBio is developing drug therapy for hemorrhagic stroke and other acute bleeding conditions. The product is an anti-fibrinolytic treatment currently in pre-clinical stage.

Therapeutic areas: NeurologyHematology
Modalities: Drug therapy
Industry: Biotech

Drug pipeline

1 asset

mutant-tPA

Pre-clinical

Indications: Hemorrhagic stroke, Intracranial bleeding, Acute bleeding conditions

Beyond the preview

Go deeper on PamBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PamBio.

Explore the full profile